Drug Trial News

RSS
COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

21 Oct 2013
Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

21 Oct 2013
Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

21 Oct 2013
Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

21 Oct 2013
Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

21 Oct 2013
Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

19 Oct 2013
Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

19 Oct 2013
Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

19 Oct 2013
ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

18 Oct 2013
GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

18 Oct 2013
NEJM publishes Celgene’s Abraxane phase III study results

NEJM publishes Celgene’s Abraxane phase III study results

17 Oct 2013
Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

17 Oct 2013
BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

17 Oct 2013
New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

17 Oct 2013
ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

16 Oct 2013
Researchers test ATR-101 compound in clinical trial for adrenal cancer

Researchers test ATR-101 compound in clinical trial for adrenal cancer

16 Oct 2013
Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

16 Oct 2013
Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

16 Oct 2013
Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

15 Oct 2013
immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies closes €34 million Series D financing round

15 Oct 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback